Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on March 29, 2019 by Sitemaster
Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, castration-resistant, first line, inhibitor, mCRPC, metastatic, olaparib, PARP | 4 Comments »
Posted on March 1, 2019 by Sitemaster
Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
Posted on February 26, 2019 by Sitemaster
We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, CHEIRON, combination, docetaxel, enzalutamide, mCRPC, metastatic, trial | Leave a comment »
Posted on December 27, 2018 by Sitemaster
A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: black, castration-resistant, docetaxel, mCRPC, metastatic, race, survival, white | Leave a comment »
Posted on September 25, 2018 by Sitemaster
Posted on February 5, 2018 by Sitemaster
The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, Treatment | 4 Comments »
